Enasidenib, a targeted inhibitor of mutant IDH2 proteins, for treatment of relapsed or refractory acute myeloid leukemia

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2yG3VHY
via IFTTT